ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 0202

Saudi Society for Rheumatology Consensus Recommendation on Vaccination Strategies in Adults Saudi with Autoimmune Rheumatic Disorders
Abstract Number: 0203

Risk Factors for Cytomegalovirus Infection in Patients Receiving Prolonged High-Dose Corticosteroids for Rheumatic Diseases: A Retrospective Cohort Study
Abstract Number: 0204

Immunogenicity and safety summary for the chikungunya virus-like particle vaccine development programme
Abstract Number: 0205

Implementation of the Varicella Zoster virus vaccine and its Real-World effectiveness
Abstract Number: 0206

Prospective Controlled Study of Humoral Response to Recombinant Zoster Vaccine in Cyclophosphamide-Treated Autoimmune Rheumatic Disease Patients: No Additional Impairment Compared to Other Immunosuppressive Therapies
Abstract Number: 0207

The Feasibility and Clinical Effects of Anti-Inflammatory Diet Intervention In Patients Diagnosed With Long COVID (Post-Acute Sequelae of SARS CoV-2, PASC)
Abstract Number: 0208

Current practices and challenges in tuberculosis screening and preventive treatment among patients with rheumatic diseases: A multiregional physician survey in China
Abstract Number: 0209

A Retrospective Safety Analysis based on Platelets in Arthrocentesis and Joint injections in Cancer Patients
Abstract Number: 0210

Improving Recombinant Zoster Vaccine Uptake in Younger Adults with Rheumatoid Arthritis through a Partnership with Specialty Pharmacy
Abstract Number: 0211

Initial Results From a Single-Center Quality Improvement Initiative Using the Shingrix Rheumatology Immunization Dashboard Within the Veterans Health Administration
Abstract Number: 0212

Biomarker-Guided Therapeutic Calculator for Personalized Management in Pregnant Patients with Autoimmune Rheumatic Diseases
Abstract Number: 0213

Development of a Predictive Tool for Obstetric Risk Stratification in Autoimmune Rheumatic Diseases: A Meta-Analysis-Based Model
Abstract Number: 0214

Systematic Comorbidity Screening in Inflammatory Arthritis: The Experience of a Tertiary-Care Centre
Abstract Number: 0215

Impact of Global Review on Comorbidity Management in Inflammatory Arthritis Patients
Abstract Number: 0216

Evaluation of oral treatment adherence in Systemic Lupus Erythematosus patients: indentification of risks profiles

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].